Publicacións en colaboración con investigadores/as de University of Glasgow (13)

2024

  1. Efficacy and Safety of Aficamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Results From the REDWOOD-HCM Trial, Cohort 4

    Journal of Cardiac Failure

2023

  1. Phase 2 Study of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy

    Journal of the American College of Cardiology, Vol. 81, Núm. 1, pp. 34-45

2022

  1. ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2-care pathways, treatment, and follow-up

    European Heart Journal, Vol. 43, Núm. 11, pp. 1059-1103

  2. Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial

    The Lancet Diabetes and Endocrinology, Vol. 10, Núm. 1, pp. 35-45

  3. European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1-epidemiology, pathophysiology, and diagnosis

    Cardiovascular research, Vol. 118, Núm. 6, pp. 1385-1412

  4. European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1-epidemiology, pathophysiology, and diagnosis

    European Heart Journal, Vol. 43, Núm. 11, pp. 1033-1058

2021

  1. Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure

    New England Journal of Medicine, Vol. 384, Núm. 2, pp. 105-116

  2. Empagliflozin in heart failure with a preserved ejection fraction

    New England Journal of Medicine, Vol. 385, Núm. 16, pp. 1451-1461

2020

  1. Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC-HF baseline characteristics and comparison with contemporary clinical trials

    European Journal of Heart Failure, Vol. 22, Núm. 11, pp. 2160-2171

2019

  1. Effects of serelaxin in patients with acute heart failure

    New England Journal of Medicine, Vol. 381, Núm. 8, pp. 716-726

2015

  1. Use of anticoagulants and antiplatelet agents in stable outpatients with coronary artery disease and atrial fibrillation. International CLARIFY registry

    PLoS ONE, Vol. 10, Núm. 4

2013

  1. Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: Analysis from the SHIFT study

    Clinical Research in Cardiology, Vol. 102, Núm. 1, pp. 11-22

2008

  1. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial

    The Lancet, Vol. 372, Núm. 9641, pp. 807-816